Regulations

Lilly invests heavily in UK

Lilly invests heavily in UK

US pharmaceutical major Eli Lilly has earmarked a hefty £220
million (€304 million) investment over the next four years in its
UK facilities, representing the largest investment by the firm in
any European country.

FDA panel mulls cGMP issues

FDA panel mulls cGMP issues

As this edition of In-pharmatechnologist.com goes online, the US
Food and Drug Administration is convening the inaugural meeting of
its Advisory Committee for Pharmaceutical Science's Manufacturing
Subcommittee.

Meeting GMP standards

Meeting GMP standards

Invensys APV, a supplier of process equipment to the pharmaceutical
industry, will demonstrate its new technologies at the upcoming
Achema 2003 exhibition in Frankfurt, Germany.

HQ for Euro biotech

HQ for Euro biotech

The European Federation of Biotechnology (EFB) is setting up a
trade office in Aarhus, Denmark for its activities in innovation
and functional genomics, reports Biotech Denmark on its website.

UK biotech collaboration

UK biotech collaboration

Two British firms, De Novo Pharmaceuticals and Peakdale Molecular,
are to enter into a joint collaboration to exploit their respective
skills in molecular design and chemistry synthesis, writes market
analysts Datamonitor this week.

Biogen digs into Europe

Biogen digs into Europe

Biotechnology company Biogen this week celebrated its 25th
anniversary by breaking the ground on a large-scale manufacturing
facility in Hillerød, Denmark, marking the company's first
development phase for the region and a greater...

Follow us

Product Innovations

Transforming Clinical Development

Transforming Clinical Development

The estimated cost of bringing a drug to market in the U.S. according to JAMA is $1 billion.1 The extreme cost of clinical trials urge biopharmaceutical,...

Vaccine Innovation in the Era of COVID19

Vaccine Innovation in the Era of COVID19

During this time of worldwide crisis, there is an increasing demand for the acceleration of a vaccination for COVID19. Regardless of the great recent advancements...